+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 16Years - 70Years
All Genders
ID07032285

Phase 2 Study of Oral Cirtuvivint for Advanced Soft Tissue Sarcomas Not Treatable by Surgery

Led by Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas · Updated on 2026-04-06

25

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the drug cirtuvivint as a second-line treatment for advanced soft tissue sarcomas in this Phase 2 clinical trial. The study aims to assess how well cirtuvivint works in patients with selected subtypes of advanced unresectable soft-tissue sarcomas who have progressed recently and are not candidates for surgery. This trial is conducted in Spain and plans to enroll about 25 patients. Participants will receive cirtuvivint orally at a dose of 80 mg per day, taken 5 days on and 2 days off, in 28-day cycles. The drug is supplied as tablets and taken once daily with water at the same time each day, without food at least 1 hour before and 2 hours after dosing. Treatment continues until disease progression, unacceptable side effects, or patient or investigator decision. Doses missed due to delay or vomiting are not repeated. During the study, participants will be monitored for disease progression and side effects, with evaluations including imaging and laboratory tests to confirm measurable disease and organ function. The main outcome measured is progression-free survival rate at 3 months. Patients will also provide tumor and blood samples for research. Safety and treatment adherence will be tracked throughout the trial, which lasts as long as treatment continues under study guidelines.

CONDITIONS

Brief Title

Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas

Research Team

N

Nadia Hindi, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here